Penumbra
PEN
#1771
Rank
NZ$16.29 B
Marketcap
$424.67
Share price
-0.08%
Change (1 day)
3.16%
Change (1 year)
Categories
Penumbra, Inc., is an American company that develops, manufactures and sells medical devices for neurovascular and vascular medicine applications.

P/E ratio for Penumbra (PEN)

P/E ratio as of December 2024 (TTM): 320

According to Penumbra's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 320.48. At the end of 2022 the company had a P/E ratio of < -1000.

P/E ratio history for Penumbra from 2015 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022< -1000-300.58%
2021> 1000-581.6%
2020-398-438.97%
2019117-81.76%
2018643-11.15%
2017724455.93%
2016130-77.74%
2015585

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
< -1000-434.81%๐Ÿ‡บ๐Ÿ‡ธ USA
56.4-82.41%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.